table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Rare Disease Drug Market Size Analysis from 2022 to 2027
1.5.1 Global Rare Disease Drug Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Rare Disease Drug Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Rare Disease Drug Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Rare Disease Drug Industry Impact
Chapter 2 Global Rare Disease Drug Competition by Types, Applications, and Top Regions and Countries
2.1 Global Rare Disease Drug (Volume and Value) by Type
2.1.1 Global Rare Disease Drug Consumption and Market Share by Type (2016-2021)
2.1.2 Global Rare Disease Drug Revenue and Market Share by Type (2016-2021)
2.2 Global Rare Disease Drug (Volume and Value) by Application
2.2.1 Global Rare Disease Drug Consumption and Market Share by Application (2016-2021)
2.2.2 Global Rare Disease Drug Revenue and Market Share by Application (2016-2021)
2.3 Global Rare Disease Drug (Volume and Value) by Regions
2.3.1 Global Rare Disease Drug Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Rare Disease Drug Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Rare Disease Drug Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Rare Disease Drug Consumption by Regions (2016-2021)
4.2 North America Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
4.10 South America Rare Disease Drug Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Rare Disease Drug Market Analysis
5.1 North America Rare Disease Drug Consumption and Value Analysis
5.1.1 North America Rare Disease Drug Market Under COVID-19
5.2 North America Rare Disease Drug Consumption Volume by Types
5.3 North America Rare Disease Drug Consumption Structure by Application
5.4 North America Rare Disease Drug Consumption by Top Countries
5.4.1 United States Rare Disease Drug Consumption Volume from 2016 to 2021
5.4.2 Canada Rare Disease Drug Consumption Volume from 2016 to 2021
5.4.3 Mexico Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 6 East Asia Rare Disease Drug Market Analysis
6.1 East Asia Rare Disease Drug Consumption and Value Analysis
6.1.1 East Asia Rare Disease Drug Market Under COVID-19
6.2 East Asia Rare Disease Drug Consumption Volume by Types
6.3 East Asia Rare Disease Drug Consumption Structure by Application
6.4 East Asia Rare Disease Drug Consumption by Top Countries
6.4.1 China Rare Disease Drug Consumption Volume from 2016 to 2021
6.4.2 Japan Rare Disease Drug Consumption Volume from 2016 to 2021
6.4.3 South Korea Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 7 Europe Rare Disease Drug Market Analysis
7.1 Europe Rare Disease Drug Consumption and Value Analysis
7.1.1 Europe Rare Disease Drug Market Under COVID-19
7.2 Europe Rare Disease Drug Consumption Volume by Types
7.3 Europe Rare Disease Drug Consumption Structure by Application
7.4 Europe Rare Disease Drug Consumption by Top Countries
7.4.1 Germany Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.2 UK Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.3 France Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.4 Italy Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.5 Russia Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.6 Spain Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.7 Netherlands Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.8 Switzerland Rare Disease Drug Consumption Volume from 2016 to 2021
7.4.9 Poland Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 8 South Asia Rare Disease Drug Market Analysis
8.1 South Asia Rare Disease Drug Consumption and Value Analysis
8.1.1 South Asia Rare Disease Drug Market Under COVID-19
8.2 South Asia Rare Disease Drug Consumption Volume by Types
8.3 South Asia Rare Disease Drug Consumption Structure by Application
8.4 South Asia Rare Disease Drug Consumption by Top Countries
8.4.1 India Rare Disease Drug Consumption Volume from 2016 to 2021
8.4.2 Pakistan Rare Disease Drug Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Rare Disease Drug Market Analysis
9.1 Southeast Asia Rare Disease Drug Consumption and Value Analysis
9.1.1 Southeast Asia Rare Disease Drug Market Under COVID-19
9.2 Southeast Asia Rare Disease Drug Consumption Volume by Types
9.3 Southeast Asia Rare Disease Drug Consumption Structure by Application
9.4 Southeast Asia Rare Disease Drug Consumption by Top Countries
9.4.1 Indonesia Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.2 Thailand Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.3 Singapore Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.4 Malaysia Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.5 Philippines Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.6 Vietnam Rare Disease Drug Consumption Volume from 2016 to 2021
9.4.7 Myanmar Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 10 Middle East Rare Disease Drug Market Analysis
10.1 Middle East Rare Disease Drug Consumption and Value Analysis
10.1.1 Middle East Rare Disease Drug Market Under COVID-19
10.2 Middle East Rare Disease Drug Consumption Volume by Types
10.3 Middle East Rare Disease Drug Consumption Structure by Application
10.4 Middle East Rare Disease Drug Consumption by Top Countries
10.4.1 Turkey Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.3 Iran Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.5 Israel Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.6 Iraq Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.7 Qatar Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.8 Kuwait Rare Disease Drug Consumption Volume from 2016 to 2021
10.4.9 Oman Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 11 Africa Rare Disease Drug Market Analysis
11.1 Africa Rare Disease Drug Consumption and Value Analysis
11.1.1 Africa Rare Disease Drug Market Under COVID-19
11.2 Africa Rare Disease Drug Consumption Volume by Types
11.3 Africa Rare Disease Drug Consumption Structure by Application
11.4 Africa Rare Disease Drug Consumption by Top Countries
11.4.1 Nigeria Rare Disease Drug Consumption Volume from 2016 to 2021
11.4.2 South Africa Rare Disease Drug Consumption Volume from 2016 to 2021
11.4.3 Egypt Rare Disease Drug Consumption Volume from 2016 to 2021
11.4.4 Algeria Rare Disease Drug Consumption Volume from 2016 to 2021
11.4.5 Morocco Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 12 Oceania Rare Disease Drug Market Analysis
12.1 Oceania Rare Disease Drug Consumption and Value Analysis
12.2 Oceania Rare Disease Drug Consumption Volume by Types
12.3 Oceania Rare Disease Drug Consumption Structure by Application
12.4 Oceania Rare Disease Drug Consumption by Top Countries
12.4.1 Australia Rare Disease Drug Consumption Volume from 2016 to 2021
12.4.2 New Zealand Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 13 South America Rare Disease Drug Market Analysis
13.1 South America Rare Disease Drug Consumption and Value Analysis
13.1.1 South America Rare Disease Drug Market Under COVID-19
13.2 South America Rare Disease Drug Consumption Volume by Types
13.3 South America Rare Disease Drug Consumption Structure by Application
13.4 South America Rare Disease Drug Consumption Volume by Major Countries
13.4.1 Brazil Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.2 Argentina Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.3 Columbia Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.4 Chile Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.5 Venezuela Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.6 Peru Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Rare Disease Drug Consumption Volume from 2016 to 2021
13.4.8 Ecuador Rare Disease Drug Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Rare Disease Drug Business
14.1 Novartis AG
14.1.1 Novartis AG Company Profile
14.1.2 Novartis AG Rare Disease Drug Product Specification
14.1.3 Novartis AG Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Bristol-Myers Squibb Company
14.2.1 Bristol-Myers Squibb Company Company Profile
14.2.2 Bristol-Myers Squibb Company Rare Disease Drug Product Specification
14.2.3 Bristol-Myers Squibb Company Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Celgene Corporation
14.3.1 Celgene Corporation Company Profile
14.3.2 Celgene Corporation Rare Disease Drug Product Specification
14.3.3 Celgene Corporation Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 F. Hoffmann-La Roche Ltd.
14.4.1 F. Hoffmann-La Roche Ltd. Company Profile
14.4.2 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Specification
14.4.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Pfizer, Inc.
14.5.1 Pfizer, Inc. Company Profile
14.5.2 Pfizer, Inc. Rare Disease Drug Product Specification
14.5.3 Pfizer, Inc. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Sanofi S.A.
14.6.1 Sanofi S.A. Company Profile
14.6.2 Sanofi S.A. Rare Disease Drug Product Specification
14.6.3 Sanofi S.A. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Alexion Pharmaceuticals, Inc.
14.7.1 Alexion Pharmaceuticals, Inc. Company Profile
14.7.2 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Specification
14.7.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Eli Lilly and Company
14.8.1 Eli Lilly and Company Company Profile
14.8.2 Eli Lilly and Company Rare Disease Drug Product Specification
14.8.3 Eli Lilly and Company Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Novo Nordisk A/S
14.9.1 Novo Nordisk A/S Company Profile
14.9.2 Novo Nordisk A/S Rare Disease Drug Product Specification
14.9.3 Novo Nordisk A/S Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 AstraZeneca
14.10.1 AstraZeneca Company Profile
14.10.2 AstraZeneca Rare Disease Drug Product Specification
14.10.3 AstraZeneca Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Eisai Co., Ltd.
14.11.1 Eisai Co., Ltd. Company Profile
14.11.2 Eisai Co., Ltd. Rare Disease Drug Product Specification
14.11.3 Eisai Co., Ltd. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Daiichi Sankyo Company Limited
14.12.1 Daiichi Sankyo Company Limited Company Profile
14.12.2 Daiichi Sankyo Company Limited Rare Disease Drug Product Specification
14.12.3 Daiichi Sankyo Company Limited Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Bayer AG
14.13.1 Bayer AG Company Profile
14.13.2 Bayer AG Rare Disease Drug Product Specification
14.13.3 Bayer AG Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 GlaxoSmithKline
14.14.1 GlaxoSmithKline Company Profile
14.14.2 GlaxoSmithKline Rare Disease Drug Product Specification
14.14.3 GlaxoSmithKline Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Merck & Co., Inc.
14.15.1 Merck & Co., Inc. Company Profile
14.15.2 Merck & Co., Inc. Rare Disease Drug Product Specification
14.15.3 Merck & Co., Inc. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.16 Johnson & Johnson
14.16.1 Johnson & Johnson Company Profile
14.16.2 Johnson & Johnson Rare Disease Drug Product Specification
14.16.3 Johnson & Johnson Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.17 Biogen, Inc.
14.17.1 Biogen, Inc. Company Profile
14.17.2 Biogen, Inc. Rare Disease Drug Product Specification
14.17.3 Biogen, Inc. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.18 Shire
14.18.1 Shire Company Profile
14.18.2 Shire Rare Disease Drug Product Specification
14.18.3 Shire Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.19 Amgen, Inc.
14.19.1 Amgen, Inc. Company Profile
14.19.2 Amgen, Inc. Rare Disease Drug Product Specification
14.19.3 Amgen, Inc. Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.20 Deciphera
14.20.1 Deciphera Company Profile
14.20.2 Deciphera Rare Disease Drug Product Specification
14.20.3 Deciphera Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.21 Atara Biotherapeutics
14.21.1 Atara Biotherapeutics Company Profile
14.21.2 Atara Biotherapeutics Rare Disease Drug Product Specification
14.21.3 Atara Biotherapeutics Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.22 ProQR
14.22.1 ProQR Company Profile
14.22.2 ProQR Rare Disease Drug Product Specification
14.22.3 ProQR Rare Disease Drug Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Rare Disease Drug Market Forecast (2022-2027)
15.1 Global Rare Disease Drug Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Rare Disease Drug Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Rare Disease Drug Value and Growth Rate Forecast (2022-2027)
15.2 Global Rare Disease Drug Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Rare Disease Drug Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Rare Disease Drug Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Rare Disease Drug Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Rare Disease Drug Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Rare Disease Drug Consumption Forecast by Type (2022-2027)
15.3.2 Global Rare Disease Drug Revenue Forecast by Type (2022-2027)
15.3.3 Global Rare Disease Drug Price Forecast by Type (2022-2027)
15.4 Global Rare Disease Drug Consumption Volume Forecast by Application (2022-2027)
15.5 Rare Disease Drug Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
